ClinicalTrials.gg
CompletedNCT01475032PAED2/FRESHUpdated Mar 29, 2017

Efficacy Study of the Product "CHF 1535" Versus Beclomethasone (BDP) and Free Combo in Asthmatic Children

A Phase 3 interventional study of CHF 1535 and Beclomethasone (BDP) in Asthma, sponsored by Chiesi Farmaceutici S.p.A.. Completed at 11 sites in 11 countries. Open to participants aged 5 Years to 11 Years. Per ClinicalTrials.gov, last updated 2017-03-29.

Sponsored by Chiesi Farmaceutici S.p.A. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
638
Allocation
Randomized
Ages
5 Years to 11 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 40 studies testing beclomethasone in Asthma — none open to participants now, none under way, none of them phase 3. Beclomethasone · Asthma.

Enrollment
5th of 40
638 · median 67
Started
2011
with 1 other
Phase 3
20 of 40
none open now
Registered
18th of 40
by date
Lead sponsor
12 of 40
Chiesi Farmaceutici S.p.A.

Among the 40 studies testing beclomethasone in Asthma, this one is the 5th largest by enrollment, is one of 2 that started in 2011, is one of 20 in phase 3, and was the 18th registered.

Asthma

4,848 studies on the registry are indexed under Asthma; 603 are open to participants now.

Browse Asthma studies →

Open to participants now

None of the 40 studies testing beclomethasone in Asthma is open now. The open studies under Asthma, anywhere →

About beclomethasone

Beclomethasone: first FDA approval 1976 (VANCERIL), first EMA approval 2017. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 417 Asthma studies recruiting now, 140 (34%) set no upper age limit and 205 (49%) stop at 75 or younger; 147 take children under 18; 105 take healthy volunteers.

This study: 5 Years to 11 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 40 studies testing beclomethasone in Asthma as a file.
02

Study summary

The purpose of this study is to demonstrate that CHF 1535 in pressurized metered dose inhaler (pMDI) is non-inferior to the corresponding dose of free combination of Beclomethasone (BDP) and Formoterol Fumarate (FF) and superior to the corresponding dose of BDP in terms of lung functions in asthmatic children patients.

03

Conditions studied

  • Asthma

Browse trials for

Keywords

  • Asthma
  • children
  • chronic treatment
04

Who can participate

Ages eligible
5 Years to 11 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female children (aged ≥ 5 and \< 12 years)
  • Partly controlled asthma children according to Global Initiative for Asthma guidelines (GINA)
  • Symptomatic asthmatic patients treated with BDP up to 400 micrograms or equivalent
  • ≥ 60% and ≤ 95% of predicted normal values

Exclusion criteria

Exclusion Criteria:

  • Patients with two or more admissions to hospital for asthma exacerbation in the past 12 months or any admission to intensive care ever.
  • Occurrence of acute asthma exacerbations or lower respiratory tract infections in the 4 weeks before study entry
  • History of near fatal asthma
  • History of cystic fibrosis, bronchiectasis or primary ciliary dyskinesia
  • Diagnosis of restrictive lung disease.
  • Patients treated with systemic
  • Significant medical history and/or treatments
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
638 participants (actual)

Study arms

  • Experimental
    CHF 1535

    CHF 1535 (BDP/FF) for 12 weeks

    Drug: CHF 1535

  • Active comparator
    BDP

    BDP for 12 weeks

    Drug: Beclomethasone (BDP)

  • Active comparator
    BDP+FF

    free combo BDP+FF for 12 weeks

    Drug: Beclomethasone (BDP) + Formoterol Fumarate (FF)

Interventions

06

What researchers measure

Primary outcomes

  1. pre-dose FEV1 (forced expiratory volume in the first second)

    Assessment of lung function parameter as pre-dose FEV1

    Time frame: 12 weeks

Secondary outcomes

  1. Patient with Asthma symptoms

    Patients with Asthma symptoms

    Time frame: 12 weeks

  2. FVC (forced vital capacity)

    Assessment of lung function parameter as FVC

    Time frame: 12 weeks

  3. Rescue medication use

    rescue medication used by the patient

    Time frame: 12 weeks

  4. PEF (peak expiratory flow)

    Assessment of PEF as lung function parameter

    Time frame: 12 weeks

  5. Number of patients with adverse events

    number of adverse event per patient

    Time frame: 12 weeks

  6. Blood parameters

    Assessment of standard blood parameters (Hematology and chemistry)

    Time frame: at week 0 and week 12

  7. Heart rate

    Assessment of heart rate

    Time frame: 12 weeks

  8. Blood pressure

    Assessment of blood pressure

    Time frame: 12 weeks

07

Study locations

11 sites
  • UMHAT "Alexandrovska
    Plovdiv, 4002, Bulgaria
  • Necker Enfants Malades Hospital
    Paris, 75015, France
  • Drez. Gelb & Knecht
    Bretten, 75015, Germany
  • Micro Care Kft
    Szigetvár, 7900, Hungary
  • G.Gaslini Institute
    Genoa, 16147, Italy
  • Uniwersytetu Medycznego
    Łódź, 22 90-153, Poland
  • Spitalul Clinic Universitar de Urgenta Elias
    Bucuresti, 011461, Romania
  • Moscow State Medical University
    Moscow, 119435, Russian Federation
  • NZZ- Detská pneumologická a ftizeologická ambulanci
    Dolný Smokovec, 059 81, Slovakia
  • Hospital de Sabadell
    Barcelona, Spain
  • Institute of Pediatrics
    Kyiv, 04050, Ukraine
08

References and documents

09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2011, a primary completion of Sep 2012 and a completion of Sep 2012. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 11, 2011
First posted
Nov 21, 2011
Start
Sep 2011
Primary completionActual
Sep 2012
CompletionActual
Sep 2012
Last update
Mar 29, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 29, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01475032
Responsible party
Sponsor
First posted
Nov 21, 2011
Start date
Sep 2011
Primary completion
Sep 2012
Completion
Sep 2012
Last update
Mar 29, 2017

Study contacts

Eugenio BARALDI, MD
principal investigator · University of Padova - Italy

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: CHF 1535 · Beclomethasone · Formoterol

Start the discussion